Chester County News and Community Website
WAYNE, PA — XyloCor Therapeutics announced the completion of the Phase 1 dose-escalation component of its Phase 1/2 clinical trial (EXACT) of XC001 (encoberminogene rezmadenovec), its lead investigational gene therapy …
Read More
PHILADELPHIA, PA — Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced updated data from the ongoing Phase 1/2 clinical trial of investigational SPK-8011 in hemophilia …
Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or …
Read More
MALVERN, PA — Ocugen, Inc., (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from …
Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration recently approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who …
Read More
WEST CHESTER, PA — Papyrus Therapeutics, Inc. and Oxford Biomedica plc (LSE: OXB), a leading gene and cell therapy group, announced the signing of a research collaboration agreement.
Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, announced the U.S. Food and Drug Administration (FDA) …
Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, announced the U.S. Food and Drug Administration (FDA) …
Read MoreThe U.S. Food and Drug Administration recently approved Tecartus (brexucabtagene autoleucel), a cell-based gene therapy for treatment of adult patients diagnosed with mantle cell lymphoma (MCL) who have not responded …
Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat the whole eye, today announced the decision to discontinue the …
Read More